Lower risk of Creutzfeldt-Jakob disease in pituitary growth hormone recipients initiating treatment after 1977

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 10, 2011, Pages

  Abrams, Joseph Y ^a   Schonberger, Lawrence B ^a   Belay, Ermias D ^a   Maddox, Ryan A ^a   Leschek, Ellen W ^b   Mills, James L ^c   Wysowski, Diane K ^d   Fradkin, Judith E ^b  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE;

ARTICLE; AUTOPSY; COHORT ANALYSIS; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; CREUTZFELDT JAKOB DISEASE; DISEASE TRANSMISSION; DRUG ISOLATION; DRUG PURIFICATION; FOLLOW UP; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; NEUROPATHOLOGY; PRIORITY JOURNAL; PROBABILITY; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; COHORT STUDIES; CREUTZFELDT-JAKOB SYNDROME; FEMALE; FOLLOW-UP STUDIES; HUMAN GROWTH HORMONE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RISK;

CREUTZFELDT-JAKOB DISEASE PRION;

EID: 80053501202     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-1357     Document Type: Article

References (12)

1. Brown P, Gajdusek DC, Gibbs Jr CJ, Asher DM 1985 Potential epidemic of Creutzfeldt-Jakob disease from human growth hormone therapy. N Engl J Med 313:728-731 (Pubitemid 15232427)
2. Fradkin JE, Schonberger LB, Mills JL, Gunn WJ, Piper JM, Wysowski DK, Thomson R, Durako S, Brown P 1991 Creutzfeldt-Jakob disease in pituitary growth hormone recipients in the United States. JAMA 265:880-884
3. Taylor DM, Dickinson AG, Fraser H, Robertson PA, Salacinski PR, Lowry PJ 1985 Preparation of growth hormone free from contamination from unconventional slow viruses. Lancet 2:260-262
4. Belay ED, Schonberger LB 2005 The public health impact of prion diseases. Annu Rev Public Health 26:191-212 (Pubitemid 40547381)
5. Mills JL, Fradkin J, Schonberger L, Gunn W, Thomson RA, Piper J, Wysowski D, Brown P 1990 Status report on the U.S. human growth hormone recipient follow-up study. Horm Res 33:116-120 (Pubitemid 20261738)
6. New MI, Brown P, Temeck JW, Owens C, Hedley-Whyte ET, Richardson EP 1988 Preclinical Creutzfeldt-Jakob disease discovered at autopsy in a human growth hormone recipient. Neurology 38:1133-1134
7. Prusiner SB, Cochran SP, Groth DF, Downey DE, Bowman KA, Martinez HM 1982 Measurement of the scrapie agent using an incubation time interval assay. Ann Neurol 11:353-358 (Pubitemid 12133693)
8. Pocchiari M, Peano S, Conz A, Eshkol A, Maillard F, Brown P, Gibbs Jr CJ, Xi YG, Tenham-Fisher E, Macchi G 1991 Combination ultrafiltration and 6 M urea treatment of human growth hormone effectively minimizes risk from potential Creutzfeldt-Jakob disease virus contamination. Horm Res 35:161-166
9. Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I, Fletcher A, Will RG, Pocchiari M, Cashman NR, d'Aignaux JH, Cervenáková L, Fradkin J, Schonberger LB, Collins SJ 2000 Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology 55:1075-1081
10. Boyd A, Klug GM, Schonberger LB, McGlade A, Brandel JP, Masters CL, Collins SJ 2010 Iatrogenic Creutzfeldt-Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients? Med J Aust 193:366-369
11. Furtner M, Gelpi E, Kiechl S, Knoflach M, Zangerl A, Gotwald T, Willeit J, Maier H, Ströbel T, Unterberger U, Budka H 2008 Iatrogenic Creutzfeldt-Jakob disease 22 years after human growth hormone therapy: clinical and radiological features. J Neurol Neurosurg Psychiatry 79:229-231 (Pubitemid 351236570)
12. Brown P, Brandel JP, Preece M, Preese M, Sato T 2006 Iatrogenic Creutzfeldt-Jakob disease: the waning of an era. Neurology 67:389-393 (Pubitemid 44214958)